The French Agency for the Safety of Health Products (Afssaps) has announced that the specialties based on rosiglitazone, that is to say the drugs Avandia and Avandamet which are indicated in the treatment of diabetes, will be withdrawn from the market as soon as on November 3. As announced in September, this decision follows the conclusions of the European Medicines Agency (EMA) which considers that the benefit / risk ratio of rosiglitazone is unfavorable due to an increased cardiovascular risk.
Rosiglitazone is indicated for the treatment of type 2 diabetes to improve blood sugar control and prevent complications associated with diabetic “microangiopathy”. About 110,000 people are currently being treated with Avandia or Avandamet. If you are one of them, it is important to consult your doctor as soon as possible in order to adapt your treatment.
